We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

IBC Announces Next Generation Protein Therapeutics Summit

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

IBC Life Sciences is pleased to announce the Next Generation Protein Therapeutics Summit taking place on June 21-23, 2010 at the Marriot San Francisco Airport in Burlingame, CA.

Featuring four conferences, this summit will bring together companies and academics from different disciplines to cross-fertilize ideas, share new data, and discuss strategies that will help turn promising molecules into products. Conferences featured at the summit, include:

- Beyond Antibodies
Novel Scaffolds and Preclinical – Clinical Progress

- Protein Engineering & Design
Technology and Engineering to Improve Drug-Like Properties

- Immunogenicity of Biologics
De-Immunization and Risk-Mitigation Strategies

- Crossing the Barriers
BBB & Membranes, Intracellular Targeting and Alternative Protein Delivery

Attendees will hear keynote presentations from Dr. James D. Marks, a professor at the University of California, San Francisco, Dr. Andreas Plückthun, professor of Biochemistry at the University of Zurich and Dr. Carlos Barbas, Kellogg Professor and Chair at the Scripps Research Institute.

The program also includes two featured presentations by the FDA entitled Subvisible Aggregates and their Impact on Immunogenicity and Monoclonal Antibodies, Next Generation Antibodies, and Antibody Alternatives: An FDA Perspective.  In addition, attendees will have the opportunity to interact with both FDA speakers during a panel discussion Managing Immunogenicity of Therapeutic Proteins and the Tuesday afternoon discussion, Regulatory issues associated with the next generation protein therapeutics.

The program features luncheon discussion & debate sessions.  There will be eight topic starters to choose from lead by CEOs, Vice Presidents, and academics from across the field.  This is followed by dessert and a chance to view posters and visit the exhibit hall.

With this four conference, one venue format attendees with be able to pick and choose the presentations that best suit their needs and then come together with delegates from all events to get a wider range of perspectives and new contacts during the discussions, social events and exhibit hall visits. 

Complete event details can be found at http://www.ibclifesciences.com/ProteinSummit.

For a press pass please contact Dawn O’Connor at doconnor@ibcusa.com